Selank Where to Buy

Selank where to buy is a sequencing problem before it is a shopping problem. The order you do things in decides how much of the vial you can actually verify, and almost all of the verification happens before a cart exists rather than after a box arrives.

The short version: confirm what the molecule is supposed to be, open the batch certificate, notice that there is a second one, read the FDA entry, and only then look at the price. Everything below is research material for laboratory use and not for human consumption.

Ordering ahead of the reading is the common mistake, so here is the vendor this page checks against, placed where you will not need it until the end.

Selank where to buy: the order the checks go in

First, what is supposed to be in the vial

Selank is a synthetic heptapeptide, seven amino acids in the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. The first four residues are tuftsin, an immune peptide; the Pro-Gly-Pro tail is bolted on to slow enzymatic breakdown. PubChem lists it under CID 11765600, formula C33H57N11O9, molecular weight 751.9, CAS 129954-34-3. FDA files it under the name Selank acetate (TP-7).

Two of those numbers are the ones you will use later. The sequence tells you a listing describing Selank as a fifteen-residue or sixteen-residue peptide has copied its text from something else. The mass tells you what a mass spectrometry trace on a certificate has to land on.

Second, the certificate, and specifically its lot number

A certificate is only worth reading if it names a lot. A vendor page that shows a generic PDF with no batch number is showing you a marketing asset, not a test result, and no amount of purity printed on it means anything because it cannot be tied to the vial you would receive.

The Selank certificate published for lot 29-01260229 was issued by MZ Biolabs in Tucson, Arizona, with an analysis date of 2026-02-07. It reports 99.32% purity by HPLC-UV, with two detected peaks: the main one carrying 99.32% of the area and a single minor peak at 0.68%. Identity is confirmed by mass spectrometry against an expected monoisotopic mass of 751.43 Da, measured at 751.47 Da. That is the number from the first check, matching to two decimal places.

Third, the quantity line, which most certificates skip

The same document reports a measured quantity of 12.29 mg per vial against a 10 mg label. Publishing an assayed fill weight at all is unusual, and publishing one above the label is more unusual still. It is a single lot measured on a single date rather than a guarantee, so do not fold it into a per-mg calculation and treat the result as what you are buying. What it tells you is that the vendor published a figure that could have embarrassed it, which is a different signal from a page that only publishes flattering ones.

Fourth, the second certificate, which is the one most buyers never open

Search the February document for endotoxin. Then search it for sterility. Neither appears, and neither does LAL or pyrogen. It establishes what the powder is and how much of it there is, and it says nothing about bacterial residue.

Stopping there would give you the wrong answer, because this product has two certificates and the product page only links one of them as a PDF. The second is displayed on the page as images, under a heading naming Kovera Labs and batch 29-05260628, and the underlying document is public. It is the fuller of the two by a wide margin: purity 99.371%, net content 11.86 mg against the 10 mg label, identity by LC-MS, a kinetic chromogenic LAL endotoxin test to USP Chapter 85 reporting under 0.20 EU/mL against a 0.5 EU/mL limit, a microbial sterility screen returning no growth, and heavy metals screening covering arsenic, lead and mercury.

Two certificates from two independent laboratories on the same product, one narrow and one broad. That combination is unusual in this market and it is the strongest paper signal available here, but it is only visible to someone who scrolls past the linked PDF. A buyer who reads the February report alone concludes that Selank is sold with no endotoxin data at all, which is what a great many pages about this compound currently claim.

Fifth, what the regulator has actually said

Here the competing pages get it wrong often enough that checking is worth the five minutes. Selank acetate (TP-7) appears on FDA's compounding safety page under the heading for bulk drug substances nominated but withdrawn, not under category 2. The nomination was made and then pulled by the nominator. It is not on the 503A bulks list in 21 CFR 216.23, it is not on any current category list, and it has no FDA approval for any indication.

What FDA did write, on a page current as of 22 April 2026, is worth quoting exactly once:

"Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities. FDA lacks important information regarding any safety issues raised by selank acetate administered to humans."

Read that next to check four and the sequence closes. Aggregation and peptide-related impurities are exactly what purity and identity testing look at, and immunogenicity risk for injected routes is exactly what endotoxin testing addresses. The regulator's stated concern converts directly into the lines you were searching the certificates for, which is why finding the second document matters more than any marketing claim on the page.

Selank does have a Russian anxiolytic registration, which is a real fact about Russian regulation and not evidence of efficacy by any Western standard. Reporting it is fair. Building a purchase on it is not.

Scoring the one vendor this page can actually verify

| Check | Ascension Peptides | What a fail looks like | |---|---|---| | Batch-specific certificate | Two, from two independent laboratories | Undated PDF with no lot number | | Purity by HPLC | 99.32% and 99.371% on the two batches | A percentage stated in body copy only | | Identity confirmation | 751.47 Da against 751.43 expected, plus LC-MS | No identity test, purity only | | Assayed quantity | 12.29 mg and 11.86 mg on 10 mg labels | Label weight asserted, never measured | | Endotoxin testing | On the Kovera batch only, under 0.20 EU/mL | Absent, or claimed with no test attached | | Sterility screening | On the Kovera batch only, no growth | Absent, or claimed with no test attached | | Documents easy to find | No; only the narrower PDF is linked | Nothing published at all | | Domestic stock | Ships from the US, same-day cutoff 2pm CST | Handling window in business days | | Human-use claims | None; sold as research material | Dosing charts on the product page |

Eight of nine are strong, and the one weak result is presentation rather than substance: the more thorough certificate is the harder of the two to reach. That is a good score for this market, and it is only visible to someone who looked for the second document.

On price, the 10 mg vial lists at $47.50, reduced from $60.00, and falls to $23.75 with the code PEPTIDEDECK. That is $2.38 per milligram on the label weight. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price, and nothing published says those tiers stack with the code, so do not plan around it. Free shipping starts at $250, which one discounted vial does not reach. The vendor states lyophilised storage at minus 20 degrees Celsius in a dry, dark place, and 4 degrees once reconstituted.

The two checks you cannot finish before paying

Everything above is done in a browser. Two criteria resist that, and pretending otherwise is how buying guides mislead people.

The first is where the vial physically sits. A supplier holding domestic stock publishes a dispatch cutoff as a clock time, because that is a promise only inventory in a warehouse can support. A supplier without it publishes a handling window counted in business days, and that phrasing is doing quiet work: it is the gap in which an order is placed with someone else and then forwarded to you. You can read the difference before you pay, and you only confirm it when a tracking number appears and either originates in your country or does not.

The second is what happens when something goes wrong. Refund policies here usually cover shipping damage and little else, which is defensible for research material and worth knowing in advance. What matters more is whether there is a business in your jurisdiction to complain to at all. A domestic seller is one your consumer rules reach and one a carrier claim can be filed against; an overseas storefront billing through an offshore processor is neither, and no amount of certificate quality changes that. This is the reason a cheaper landed price from a foreign warehouse is rarely the better purchase.

What a failing listing looks like from the outside

The tells are consistent across this market, and none of them require you to be a chemist.

No lot number anywhere on the page or the PDF. A purity figure typed into the description with no document behind it. A molecular description that does not match the seven-residue sequence. Dosing guidance of any kind, which means the seller has abandoned the research-use basis of its own sale. And the quiet one: an active claim of sterility with no test attached, which is worse than no claim at all.

Common questions

Keep exploring

The same certificate discipline applied to a different compound is in the BPC-157 pre-checkout checklist, which is useful because BPC-157 sits in the same withdrawn-nomination position on the FDA page. If grade and testing scope are what you want to compare across products, how NAD+ buyers read grade before anything else covers a case where the clinic channel genuinely exists. And for the version of this sequence written around a compound with no published human data at all, see the retatrutide route from first search to first vial.